INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8401, 30919, 'Midazolam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8402, 0, 'Mifepristone', 'Uterine Hemorrhage', 'Mifepristone is contraindicated in women with unexplained vaginal bleeding, and women with endometrial hyperplasia with atypia or endometrial carcinoma, as it promotes endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and vaginal bleeding.  It should also be used with caution in women with hemorrhagic disorders or those receiving anticoagulation therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8403, 0, 'Mifepristone', 'Cardiovascular Diseases', 'Mifepristone does not reduce serum cortisol levels, and elevated cortisol levels might activate mineralocorticoid receptors which are expressed in cardiac tissue.  Caution should be used in patients with underlying heart conditions, including heart failure and coronary vascular disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8404, 0, 'Mifepristone', 'Hepatic Insufficiency', 'There is limited information on the safety of mifepristone in patients with mild to moderate hepatic impairment, hence the manufacturers recommend that the maximum dose should not exceed 600 mg per day.  The use of mifepristone is not recommended in patients with severe hepatic disease as the pharmacokinetics in these patients have not been studied.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8405, 0, 'Mifepristone', 'Long QT Syndrome', 'Mifepristone prolongs the QTc interval in a dose-related manner.  There is little or no experience with high exposure, concomitant dosing with other QT- prolonging drugs, or potassium channel variants resulting in long QT interval.  Caution and monitoring is advised if used in patients with long QT.  To minimize risk, the lowest effective dose should always be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8406, 0, 'Mifepristone', 'Kidney Diseases', 'No change in the initial dose of mifepristone is needed for renal impairment; but the manufacturers recommend that the maximum dose should not exceed 600 mg per day in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8407, 23149, 'Micafungin', 'Liver Diseases', 'Laboratory abnormalities in liver function tests have been observed in healthy volunteers and patients treated with echinocandins, and clinical hepatic abnormalities have occurred in some patients with serious underlying conditions who were receiving multiple concomitant medications with echinocandin therapy.  Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have also been reported, although a causal relationship has not been established.  Therapy with echinocandins should be administered cautiously in patients with preexisting liver disease.  Liver function should be monitored regularly during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8408, 23149, 'Micafungin', 'Anemia', 'Acute, transient, and asymptomatic intravascular hemolysis and hemoglobinuria were reported in a healthy volunteer given an infusion of micafungin 200 mg and oral prednisolone 20 mg.  Isolated cases of significant hemolysis and hemolytic anemia have also been reported in patients treated with micafungin.  Therapy with micafungin should be administered cautiously in patients with preexisting anemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8409, 23149, 'Micafungin', 'Kidney Diseases', 'Elevations in BUN and creatinine, as well as isolated cases of significant renal dysfunction or acute renal failure, have been reported in patients treated with micafungin.  In controlled clinical trials, the incidence of drug-related renal adverse events was 0.4% for patients receiving micafungin and 0.5% for patients receiving fluconazole.  Therapy with micafungin should be administered cautiously in patients with preexisting renal impairment.  Renal function should be monitored regularly during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8410, 0, 'Midostaurin', 'Liver Failure', 'Midostaurin should be used with caution in patients with severe hepatic or severe renal dysfunction as the pharmacokinetics of this agent have not been studied on these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8411, 0, 'Midostaurin', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8412, 2158, 'Mineral oil', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8413, 31999, 'Mineral oil', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8414, 2158, 'Mineral oil', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8415, 31999, 'Mineral oil', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8416, 2158, 'Mineral oil', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8417, 31999, 'Mineral oil', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8418, 2158, 'Mineral oil', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8419, 31999, 'Mineral oil', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8420, 25236, 'Milrinone', 'Arrhythmias, Cardiac', 'The use of milrinone both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia.  Long-term oral use has been associated with an increased risk of sudden death.  Hence, patients receiving milrinone should be observed closely with the use of continuous electrocardiographic monitoring to allow the prompt detection and management of ventricular arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8421, 25236, 'Milrinone', 'Heart Valve Diseases', 'Milrinone should not be used in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction.  Like other inotropic agents, it may aggravate outflow tract obstruction in hypertrophic subaortic stenosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8422, 25236, 'Milrinone', 'Myocardial Infarction', 'No clinical studies have been conducted with milrinone in patients in the acute phase of post myocardial infarction.  Until further clinical experience with this class of drugs is gained, milrinone is not recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8423, 25236, 'Milrinone', 'Liver Diseases', 'The use of inamrinone (former amrinone) has been associated with hepatotoxicity, manifested as marked alterations in liver function tests and clinical symptoms suggestive of idiosyncratic hypersensitivity.  This especially after long-term use.  Therapy with inamrinone should be administered cautiously if at all in patients with liver disease and discontinuation of the drug may be required if symptoms worsen.  Monitoring of liver functions tests prior to and during therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8424, 25236, 'Milrinone', 'Hypotension', 'The use of amrinone or milrinone is associated with a fall in blood pressure.  Some patients have required correction by intravenous infusion of plasma.  Therapy with amrinone or milrinone should be administered cautiously in hypotensive patients.  Monitoring fluid and electrolyte status, renal function, blood pressure, and heart rate is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8425, 25236, 'Milrinone', 'Thrombocytopenia', 'The use of amrinone, and infrequently, milrinone, can cause thrombocytopenia.  This appears to be dose-dependent and usually occurs during prolonged therapy.  Therapy with amrinone and milrinone should be administered cautiously in patients with thrombocytopenia.  The dosage may need to be reduced or the drug discontinued if platelet count falls below 150,000/mm3 or if symptoms develop.  Platelet counts prior and during therapy are recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8426, 32280, 'Miglustat', 'Inflammatory Bowel Diseases', 'The safety of treatment with miglustat has not been evaluated in patients with significant gastrointestinal disease, such as inflammatory bowel disease.  Continued treatment of these patients with miglustat should occur only after careful consideration of the risks and benefits of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8427, 32280, 'Miglustat', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported in patients treated with miglustat.  It is recommended to assess all patients receiving miglustat for peripheral neuropathy at the beginning and at 6 months interval of starting treatment.  Caution should be instituted in patients who develop symptoms of peripheral neuropathy and cessation of therapy may be considered if appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8428, 32280, 'Miglustat', 'Kidney Diseases', 'Miglustat is substantially excreted by the kidney.  The use of miglustat in patients with severe renal impairment is not recommended (CrCl < 30 mL/min).  In patients with moderate renal impairment miglustat administration should be initiated at a dose of 100 mg once a day, and in those patients with mild renal impairment, it should be started at 100 mg twice per day.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8429, 32280, 'Miglustat', 'Thrombocytopenia', 'Miglustat can cause a mild reduction in platelet counts.  Monitoring of platelet counts is recommended, especially in patients with preexisting thrombocytopenia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8430, 0, 'Minocycline (topical)', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8431, 2385, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8432, 6240, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8433, 15165, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8434, 15166, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8435, 15358, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8436, 22818, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8437, 22820, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8438, 22821, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8439, 30201, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8440, 30553, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8441, 32460, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8442, 33813, 'Mirabegron', 'Urinary Retention', 'Although an increased risk of urinary retention was not observed in a controlled clinical safety study in patients with bladder outlet obstruction, urinary retention has been reported in this population during postmarketing use.  Therapy with mirabegron should be administered cautiously in patients with clinically significant bladder outlet obstruction and conditions predisposing to urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8443, 2385, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8444, 6240, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8445, 15165, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8446, 15166, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8447, 15358, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8448, 22818, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8449, 22820, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8450, 22821, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8451, 30201, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8452, 30553, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8453, 32460, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8454, 33813, 'Mirabegron', 'Hypertension', 'Mirabegron can increase blood pressure.  In clinical studies, the use of mirabegron was associated with dose-related increases in supine blood pressure.  At the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo in healthy volunteers and approximately 0.5 to 1 mmHg greater than placebo in patients with overactive bladder.  Worsening of preexisting hypertension was reported infrequently in patients receiving mirabegron.  Therapy with mirabegron should be administered cautiously in patients with hypertension.  Periodic blood pressure determinations are recommended.  Mirabegron is not recommended for use in patients with severe, uncontrolled hypertension, defined as systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8455, 2385, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8456, 6240, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8457, 15165, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8458, 15166, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8459, 15358, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8460, 22818, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8461, 22820, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8462, 22821, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8463, 30201, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8464, 30553, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8465, 32460, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8466, 33813, 'Mirabegron', 'Liver Diseases', 'Mirebegron is partially metabolized by the liver through multiple pathways.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 9% and 19%, respectively, in volunteers with mild hepatic impairment (Child-Pugh Class A) and 175% and 65%, respectively, in volunteers with moderate hepatic impairment (Child-Pugh Class B) compared to volunteers with normal hepatic function.  No dosage adjustment is necessary in patients with mild hepatic impairment.  In patients with moderate hepatic impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8467, 2385, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8468, 6240, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8469, 15165, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8470, 15166, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8471, 15358, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8472, 22818, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8473, 22820, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8474, 22821, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8475, 30201, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8476, 30553, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8477, 32460, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8478, 33813, 'Mirabegron', 'Kidney Diseases', 'Mirebegron is partially eliminated by the kidney through active tubular secretion and glomerular filtration, with renal clearance accounting for approximately 25% of the total clearance.  Following administration of a single 100 mg dose, mean mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6% and 31%, respectively, in volunteers with mild renal impairment (estimated GFR 60 to 89 mL/min/1.73 m2), 23% and 66%, respectively, in volunteers with moderate renal impairment (estimated GFR 30 to 59 mL/min/1.73 m2), and 92% and 118%, respectively, in patients with severe renal impairment (estimated GFR 15 to 29 mL/min/1.73 m2) compared to volunteers with normal renal function.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the daily dosage of mirabegron should not exceed 25 mg.  Mirabegron has not been studied in patients with end stage renal disease (CrCl <15 mL/min or estimated GFR <15 mL/min/1.73 m2 or requirement for hemodialysis).  Mirabegron is not recommended for use in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8479, 3269, 'Misoprostol', 'Cardiovascular Diseases', 'Caution should be employed when administering misoprostol to patients with preexisting cardiovascular disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8480, 12026, 'Misoprostol', 'Cardiovascular Diseases', 'Caution should be employed when administering misoprostol to patients with preexisting cardiovascular disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8481, 22846, 'Misoprostol', 'Cardiovascular Diseases', 'Caution should be employed when administering misoprostol to patients with preexisting cardiovascular disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8482, 3269, 'Misoprostol', 'Diarrhea', 'Diarrhea may occur in up to 40% of patients receiving misoprostol.  Misoprostol should be administered cautiously in patients with underlying conditions such as inflammatory bowel disease and dehydration.  Careful monitoring during therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8483, 12026, 'Misoprostol', 'Diarrhea', 'Diarrhea may occur in up to 40% of patients receiving misoprostol.  Misoprostol should be administered cautiously in patients with underlying conditions such as inflammatory bowel disease and dehydration.  Careful monitoring during therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8484, 22846, 'Misoprostol', 'Diarrhea', 'Diarrhea may occur in up to 40% of patients receiving misoprostol.  Misoprostol should be administered cautiously in patients with underlying conditions such as inflammatory bowel disease and dehydration.  Careful monitoring during therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8485, 8238, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8486, 9826, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8487, 13087, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8488, 14323, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8489, 22839, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8490, 22841, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8491, 25853, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8492, 29838, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8493, 33212, 'Mirtazapine', 'Liver Diseases', 'Mirtazapine is extensively metabolized by the liver.  Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney.  The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment.  Therapy with mirtazapine should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8494, 8238, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8495, 9826, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8496, 13087, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8497, 14323, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8498, 22839, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8499, 22841, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8500, 25853, 'Mirtazapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '', 'DDInter', 0);
